Litcius/Paper detail

Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial

Guy Jérusalem, Thomas E. Delea, Migule Martin, Michelino De Laurentiis, Arnd Nusch, J. Thaddeus Beck, Arlene Chan, Seock‐Ah Im, Patrick Neven, Alexander Lonshteyn, David Chandiwana, Brad Lanoue, Peter A. Fasching

2021Clinical Breast Cancer24 citationsDOI

Topics & Concepts

MedicineFulvestrantPlaceboInternal medicineBreast cancerAdverse effectHazard ratioCancerPostmenopausal womenTwistGynecologyOncologyGastroenterologyEstrogen receptorConfidence intervalGeometryAlternative medicineMathematicsPathologyAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial | Litcius